MAIN MENU
QUICK LINKS
CONNECT WITH US

Button

Rheumatology and Clinical Immunology: Clinical Research

The division of Rheumatology and Clinical Immunology is actively involved in research and is activity recruiting Rheumatoid Arthritis patients for clinical trials. We have a number of short and long-term clinical trials underway involving the use of new and some already approved therapies for the treatment of Rheumatoid Arthritis.

We are also deeply interested in looking after and advancing care of patients with Psoriatic arthritis and Ankylosing Spondylitis. Other interests include use of ultrasound as surrogate measures of cardiovascular co-morbidity. The division is also actively involved in outcome and cost utilization research using large Medicare databases.

For further information and to see if you may qualify for one of our studies, please contact our Research Coordinator at Sarah.Walters@jax.ufl.edu.

A Multicenter, Double-blind, Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Subjects with Rheumatoid Arthritis

A Phase 2, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Filgotinib and GS-9876 in Subjects with Lupus Membranous Nephropathy (LMN)

A PHASE 3B/4 RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF METHOTREXATE (MTX) WITHDRAWAL IN SUBJECTS WITH RHEUMATOID ARTHRITIS (RA) TREATED WITH TOFACITINIB 11MG MODIFIED RELEASE (MR) FORMULATION (A3921192)

A3921133 Phase 3B/4 Randomized Safety Endpoint Study of 2 Doses of Taofacitinib in Comparison to a Tumor Necrosis Factor (TNF) Inhibitor in Subjects with Rheumatoid Arthritis

GS-US-417-0301: A Randomized, Double-blind, Placebo-and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 weeks in Combination with Methotrexate to Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

GS-US-417-0303: A Randomized, Double-blind, Placebo-and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 Weeks Alone and in Combination with Methotrexate (MTX) to Subjects with Moderately to Severly Active Rheumatoid Arthritis Who Are Naïve to MTX Therapy

GS-US-445-4189- A Randomized, Phase 2, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Filgotinib, GS-9876 and GS-4059 in Adult Subjects with Active Sjogren’s Syndrome

M12-538 Phase 2 Study, Multicenter, Open-Label Extension (OLE) Study in Rheumatoid Arthiritis Subjects Who Have Completed a Preceding Phase 2 Randomized Controlled Trial (RCT) with ABT-494

1